# MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT06132256** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Syndax Pharmaceuticals** · enrollment: 145 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Axatilimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06132256
- **Lead sponsor:** Syndax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-11
- **Primary completion:** 2026-09
- **Final completion:** 2026-11
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06132256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06132256, "MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06132256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*